excel bex pharma

Upload: midul-khan

Post on 02-Apr-2018

232 views

Category:

Documents


0 download

TRANSCRIPT

  • 7/27/2019 Excel Bex Pharma

    1/44

    Income statement

    2007

    Net Sales Revenue 3,597,024,812

    Cost of Goods Sold 1,967,509,975

    Gross Profit 1,629,514,837

    Operating Expenses 974,736,690Administrative Expenses 145,544,701

    Selling, Marketing and Distribution Expenses 829,191,989

    Profit from Operations 654,778,147

    Other Income 19,625,795

    Finance Cost 245,742,392

    Profit Before Contribution to WPPF 419,661,550

    Contribution to Workers' Profit Participation/ Welfare Funds 19,983,883

    Profit Before Tax 399,677,667

    Income Tax Expense 46,609,789

    current tax 57,661,278

    deffered tax 11,051,489

    Profit After Tax Transferred to Statement of Changes in Equity 353,067,87815%

    Dividend 52960181.7

    Transfer to reserve 300,107,696

    Depreciation 1,523,087,739

    EPS 3

    Number of shares used to compute EPS 114,507,043

  • 7/27/2019 Excel Bex Pharma

    2/44

    2008 2009 2010 2011

    4,010,167,059 4868254915 6,490,847,353 7,890,241,843

    2002871181 2566206626 3,317,640,254 4,103,709,021

    2,007,295,878 2302048289 3,173,207,099 3,786,532,822

    1,008,501,030 1300765878 1,537,426,907 1,798,053,124153,464,243 215192547 233,413,980 275,201,846

    855,036,787 1085573331 1,304,012,927 1,522,851,278

    998,794,848 1001282411 1,635,780,192 1,988,479,698

    686,510 198986379 456,011,134 340,907,774

    249,654,298 289427992 662,182,384 567,645,757

    749,827,060 910840798 1,429,608,942 1,761,741,715

    35,706,050 49373371 68,076,616 -83,892,463

    714,121,010 867467427 1,361,532,326 1,677,849,252

    168,779,737 242727120 309,883,518 479,323,910

    173,720,430 0 71085835 207,549,905

    4,940,693 242727120 238,797,683 271,774,005

    545,341,273 620740307 1,051,648,808 1,198,525,34230% 15% 20% 21%

    163602381.9 93111046.05 210329761.6 251690321.8

    381,738,891 527,629,261 841,319,046 946,835,020

    1,669,502,530 2654778919 3068649898 3,543,852,043

    4.33 4.13 4.18 4.76

    125,957,747 151149296 251,767,810 251,767,810

  • 7/27/2019 Excel Bex Pharma

    3/44

    2007 2008 2009

    1. Sales Growth 0.114856658 0.213978082

    Average sales growth rate

    2.COGS 0.546982598 0.499448315 0.527130701

    Average

    3.Administrative expense 0.040462524 0.03826879 0.044203221

    average

    4.Selling, Marketing and Distribution Expenses 0.230521621 0.213217249 0.22299024

    average

    5.Growth rate of other income -0.965020016 288.8521201

    Normalized growth rate

    Total loan 3,027,636,603 3,556,432,568 3,685,079,475Average loan 3,292,034,586 3,620,756,022

    Interest rate 0.075835867 0.07993579

    6.Growth rate of PPE 0.325603143 0.087703054

    Average

    7. growth rate of investment 0 -0.921478463

    average

    8. Growth rate of intangible assets 0 0

    normalized growth rate

    9. Inventory proportion to sales 0.4087134 0.375367926 0.353915995

    average

    10.Spare and supplies proportion to sales 0.050688571 0.058483929 0.049716964

    average

    11. A/R proportion to sales 0.138915025 0.125659703 0.142579167

    average

    Proportion of contribution to WPPF to sales 0.00555567 0.008903881 0.010141903

    Average

    Income tax rate 0.116618447 0.23634613 0.279811221

    Average

  • 7/27/2019 Excel Bex Pharma

    4/44

    Current tax 1.237106609 1.029273022 0

    Average

    Deferred tax 0.237106609 0.029273022 1

    Average

    Dividend portion of Net Income 0.15 0.30 0.15

    Loans, Advances and Deposits 0.190689667 0.13578215 0.143625275

    Short term investment prop. To Sales 0 0 0.513531038

    Short Term Borrowings prop. To Sales 0.252314725 0.364490109 0.298120452

    Creditors and Other Payables prop. To Sales 0.075566373 0.065627396 0.084198163

    Accrued Expense prop. To sales 0.016695114 0.02039228 0.016247075

    Dividend Payable prop. To sales 0.000913345 0.000790383 0.000354896

    Income Tax Payable 0.011574546 0.035928019 0.014498929

    Cash inflow from sale of assets

    Depreciation rate 0.169364783 0.140046334 0.204739989

    Average

    Number of shares Outstanding 0.099999997 0.199999997

  • 7/27/2019 Excel Bex Pharma

    5/44

    2010 2011 2012 2013 2014 2015

    0.333300632 0.215595039

    0.219432603 0.219432603 0.219432603 0.219432603 0.219432603

    0.511125909 0.52009927

    0.520957359 0.520957359 0.520957359 0.520957359 0.520957359

    0.035960479 0.034878759

    0.038754755 0.038754755 0.038754755 0.038754755 0.038754755

    0.200900261 0.193004385

    0.212126751 0.212126751 0.212126751 0.212126751 0.212126751

    1.291670095 -0.252413486

    0.11 0.11 0.11 0.11 0.11

    3,890,972,228 3,896,034,840 4,537,396,079 4,740,289,780 5,070,653,773 5,556,459,1983,788,025,852 3,893,503,534 4,216,715,460 4,638,842,929 4,905,471,777 5,313,556,486

    0.174809362 0.14579305

    0.119093517 0.119093517 0.119093517 0.119093517 0.119093517

    0.166328972 0.041140893

    0.155194015 0.155194015 0.155194015 0.155194015 0.155194015

    1.185602462 -0.45205021

    -0.046981553 -0.046981553 -0.046981553 -0.046981553 -0.046981553

    7.928076626 1.658756962

    0.155 0.155 0.155 0.155 0.155

    0.305631813 0.290465701

    0.346818967 0.346818967 0.346818967 0.346818967 0.346818967

    0.042601555 0.041301807

    0.048558565 0.048558565 0.048558565 0.048558565 0.048558565

    0.126540711 0.123979003

    0.131534722 0.131534722 0.131534722 0.131534722 0.131534722

    0.010488094 -0.010632432

    0.004891423 0.004891423 0.004891423 0.004891423 0.004891423

    0.22759909 0.285677578

    0.229210493 0.229210493 0.229210493 0.229210493 0.229210493

  • 7/27/2019 Excel Bex Pharma

    6/44

    0.22939534 0.433005533

    0.585756101 0.585756101 0.585756101 0.585756101 0.585756101

    0.77060466 0.566994467

    0.520795752 0.520795752 0.520795752 0.520795752 0.520795752

    0.20 0.21

    0.202 0.202 0.202 0.202 0.202

    0.120035117 0.106501261

    0.139326694 0.139326694 0.139326694 0.139326694 0.139326694

    0.13240239 0.27799193

    0.184785072 0.184785072 0.184785072 0.184785072 0.184785072

    0.252657467 0.208132531

    0.275143057 0.275143057 0.275143057 0.275143057 0.275143057

    0.066603886 0.066385562

    0.071676276 0.071676276 0.071676276 0.071676276 0.071676276

    0.013944586 0.012871585

    0.016030128 0.016030128 0.016030128 0.016030128 0.016030128

    0.000232312 0.000172549

    0.000492697 0.000492697 0.000492697 0.000492697 0.000492697

    0 0.0019622080.01279274 0.01279274 0.01279274 0.01279274 0.01279274

    -2,443,606,226 -2,822,839,289 -3,260,927,053 -3,767,003,417 -4,351,619,804

    0.202908665 0.22507089

    0.188426132 0.188426132 0.188426132 0.188426132 0.188426132

    0.665689597 0

    0.241422398 0.241422398 0.241422398 0.241422398 0.241422398

  • 7/27/2019 Excel Bex Pharma

    7/44

    2016

    0.219432603

    0.520957359

    0.038754755

    0.212126751

    0.11

    6,231,814,9715,894,137,084

    0.119093517

    0.155194015

    -0.046981553

    0.155

    0.346818967

    0.048558565

    0.131534722

    0.004891423

    0.229210493

  • 7/27/2019 Excel Bex Pharma

    8/44

    0.585756101

    0.520795752

    0.202

    0.139326694

    0.184785072

    0.275143057

    0.071676276

    0.016030128

    0.000492697

    0.01279274

    0.188426132

  • 7/27/2019 Excel Bex Pharma

    9/44

    Balance Sheet

    2007

    ASSETNon-Current Assets 9,029,643,482

    Property, Plant and Equipment- Carrying Value 8,992,942,392

    Investment in Shares 36,701,090

    Intangible Assets 0

    Current Assets 2,923,775,458

    Inventories 1,470,152,242

    Spares & Supplies 182,328,049

    Accounts Receivable 499,680,792

    Loans, Advances and Deposits 685,915,465

    Short Term Investment 0

    Cash and Cash Equivalents 85,698,910

    TOTAL ASSETS 11,953,418,940SHAREHOLDERS' EQUITY AND LIABILITIES

    Shareholders' Equity 8,250,939,647

    Issued Share Capital 1,145,070,430

    Share Premium 1,489,750,000

    Excess of Issue Price over Face Value of GDRs 1,689,636,958

    Capital Reserve on Merger 294,950,950

    Revaluation Surplus 0

    Tax-Holiday Reserve 442,354,953

    Retained Earnings 3,189,176,356

    Non-Current L iabi l i t ies 2,074,506,357

    Long Term Borrowing-Net off Current Maturity (Secured) 1,776,449,778

    Fully Convertible, 5% Dividend, Preference Share 0

    Liability for Gratuity & WPPF 246,704,610

    Deferred Tax Liability 51,351,969

    Current Liabi l i t ies and Provisio ns 1,627,972,936

    Short Term Borrowings 907,582,327

    Long Term Borrowing-Current Maturity 343,604,498

    Creditors and Other Payables 271,814,118

    Accrued Expense 60,052,739

    Dividend Payable 3,285,324

    Income Tax Payable 41,633,930

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 11,953,418,940

    Total Debt 3,702,479,293

  • 7/27/2019 Excel Bex Pharma

    10/44

    2008 2009 2010 2011

    11,957,773,787 12,975,195,529 15,180,731,678 15,884,877,780

    11,921,072,697 12,966,587,178 15,123,306,298 15,745,492,625

    36,701,090 2,881,826 6,298,526 3,451,276

    0 5,726,525 51,126,854 135,933,879

    2,861,891,654 6,916,737,893 6,191,667,831 7,148,462,753

    1,505,288,093 1,722,953,284 1,983,809,444 2,291,844,631

    234,530,326 242,034,855 276,520,188 325,881,244

    503,916,401 694,111,730 821,356,439 978,224,317

    544,509,106 699,204,450 779,129,620 840,320,705

    0 2,500,000,000 859,403,704 2,193,423,560

    73,647,728 1,058,433,574 1,471,448,436 518,768,296

    14,819,665,441 19,891,933,422 21,372,399,509 23,033,340,533

    10,450,202,145 10,885,706,614 15,974,086,451 17,128,128,177

    1,259,577,470 1,511,492,960 2,098,065,090 2,517,678,100

    1,489,750,000 1,489,750,000 5,269,474,690 5,269,474,690

    1,689,636,958 1,689,636,958 1,689,636,958 1,689,636,958

    294,950,950 294,950,950 294,950,950 294,950,950

    1,711,174,747 1,617,361,714 294,950,950 1,466,602,600

    0 0 0 0

    4,005,112,020 4,282,514,032 5,087,312,943 5,889,784,879

    1,767,431,029 6,684,775,166 2,885,155,826 3,257,050,368

    1,446,600,500 1,924,933,065 1,902,150,733 1,890,074,651

    0 4,100,000,000 0 0

    274,419,253 307,425,614 335,885,792 403,598,795

    46,411,276 352,416,487 647,119,301 963,376,922

    2,602,032,267 2,321,451,642 2,513,157,232 2,648,161,988

    1,461,666,227 1,451,326,354 1,639,961,052 1,642,216,008

    648,165,841 308,820,056 348,860,443 363,744,181

    263,176,822 409,898,122 432,315,660 523,798,136

    81,776,450 79,094,905 90,512,178 101,559,917

    3,169,568 1,727,724 1,507,899 1,361,452

    144,077,359 70,584,481 0 15,482,294

    14,819,665,441 19,891,933,422 21,372,399,509 23,033,340,533

    4,369,463,296 9,006,226,808 5,398,313,058 5,905,212,356

  • 7/27/2019 Excel Bex Pharma

    11/44

    Proforma Income Statement

    2011 2012

    Net Sales Revenue 7,890,241,843 9,621,618,146

    Cost of Goods Sold 4,103,709,021 5012452774

    Gross Profit 3,786,532,822 4,609,165,372

    Operating Expenses:Administrative Expenses 275,201,846 372883450.3

    Selling, Marketing and Distribution Expenses 1,522,851,278 2041002598

    Profit from Operations 1,988,479,698 2,195,279,324

    Other Income 340,907,774 378407629.1

    Finance Cost 567,645,757 502183476.3

    Profit Before Contribution to WPPF 1,761,741,715 2,071,503,477

    Contribution to Workers' Profit Participation/ Welfare Funds 83,892,463 47063405.8

    Profit Before Tax 1,677,849,252 2,024,440,071

    Income Tax Expense 479,323,910 464022907.1

    current tax 207,549,905 271804248.7

    deffered tax 271,774,005 241661158.7

    Profit After Tax Transferred to Statement of Changes in Equity 1,198,525,342 1,560,417,164Dividend 251690321.8 315204267.2

    Transfer to reserve 946,835,020 1,245,212,897

    479,323,910 513,465,407

    1,198,525,342 1,510,974,664

  • 7/27/2019 Excel Bex Pharma

    12/44

    2013 2014 2015 2016

    11,732,914,857 14,307,498,900 17,447,030,621 21,275,477,958

    6112348331 7453596834 9089158986 11083616798

    5,620,566,526 6,853,902,067 8,357,871,635 10,191,861,160

    454706236.3 554483609.1 676155390.6 824525927.7

    2488865110 3035003258 3700981922 4513098017

    2,676,995,180 3,264,415,199 3,980,734,322 4,854,237,215

    420032468.3 466236039.9 517522004.2 574449424.7

    552456121.5 584209888.7 632810132.1 701953517.8

    2,544,571,527 3,146,441,350 3,865,446,195 4,726,733,122

    57390651.42 69984031.43 85340809.58 104067365.5

    2,487,180,875 3,076,457,319 3,780,105,385 4,622,665,757

    570087955 705156299.3 866439819.5 1059563498

    333932497.6 413049604.3 507522410.2 620645782.9

    296899385 367242404.9 451238177 551816168.2

    1,917,092,920 2,371,301,020 2,913,665,565 3,563,102,259387252769.9 479002806 588560444.2 719746656.3

    1,529,840,150 1,892,298,214 2,325,105,121 2,843,355,603

  • 7/27/2019 Excel Bex Pharma

    13/44

    Balance Sheet

    2011 2012

    ASSET

    Non-Current Assets 15,884,877,780 18349391611

    Property, Plant and Equipment- Carrying Value 15,745,492,625 18189098851

    Investment in Shares 3,451,276 3289129.695

    Intangible Assets 135,933,879 157003630.2

    Current Assets 7,148,462,753 11,005,610,699

    Inventories 2,291,844,631 3336959669

    Spares & Supplies 325,881,244 467211972.1

    Accounts Receivable 978,224,317 1265576866

    Loans, Advances and Deposits 840,320,705 1340548247

    Short Term Investment 2,193,423,560 1777931399

    Cash and Cash Equivalents 518,768,296 2,817,382,547

    TOTAL ASSETS 23,033,340,533 29,355,002,311

    SHAREHOLDERS' EQUITY AND LIABILITIES

    Shareholders' Equity 17,128,128,177 21,521,957,501Issued Share Capital 2,517,678,100 2,517,678,100

    Share Premium 5,269,474,690 5,269,474,690

    Excess of Issue Price over Face Value of GDRs 1,689,636,958 1,689,636,958

    Capital Reserve on Merger 294,950,950 294,950,950

    Revaluation Surplus 4,615,219,027 4,615,219,027

    Tax-Holiday Reserve 0 0

    Retained Earnings 5,889,784,879 7,134,997,776

    Non-Current L iabi l i t ies 3,257,050,368 3,167,760,002

    Long Term Borrowing-Net off Current Maturity (Secured) 1,890,074,651 1,512,059,721

    Fully Convertible, 5% Dividend, Preference Share 0 0

    Liability for Gratuity & WPPF 403,598,795 450,662,201

    Deferred Tax Liability 963,376,922 1,205,038,081Current Liabi l i t ies and Provisio ns 2,648,161,988 4,665,284,807

    Short Term Borrowings 1,642,216,008 2647321428

    Long Term Borrowing-Current Maturity 363,744,181 378014930.2

    Creditors and Other Payables 523,798,136 689641758.2

    Accrued Expense 101,559,917 154235770.7

    Dividend Payable 1,361,452 316,565,719

    Income Tax Payable 15,482,294 479,505,201

    TOTAL LIABILITIES 5,905,212,356 7,833,044,810

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 23,033,340,533 29,355,002,311

    Number of shares Outstanding 251,767,810 312550198.4

    EPS 4.76 4.99253295

    0.907360473

  • 7/27/2019 Excel Bex Pharma

    14/44

    2013 2014 2015 2016

    21196411934 24485299294 28284626611 32673608866

    21011938140 24272865194 28039868610 32391488414

    3134601.274 2987332.839 2846983.304 2713227.608

    181339192.9 209446767.8 241911016.9 279407224.5

    11,388,129,231 12,169,097,129 13,447,616,646 15,348,318,803

    4069197414 4962111993 6050961142 7378739294

    569733511.1 694751618.3 847202774.1 1033106684

    1543285691 1881932887 2294890318 2798464074

    1634708238 1993416521 2430837097 2964242008

    2168067513 2643812210 3223950804 3931390720

    1,403,136,864 -6,928,101 -1,400,225,489 -2,757,623,976

    32,584,541,166 36,654,396,423 41,732,243,257 48,021,927,669

    23,051,797,651 24,944,095,865 27,269,200,986 30,112,556,5892,517,678,100 2,517,678,100 2,517,678,100 2,517,678,100

    5,269,474,690 5,269,474,690 5,269,474,690 5,269,474,690

    1,689,636,958 1,689,636,958 1,689,636,958 1,689,636,958

    294,950,950 294,950,950 294,950,950 294,950,950

    4,615,219,027 4,615,219,027 4,615,219,027 4,615,219,027

    0 0 0 0

    8,664,837,926 10,557,136,140 12,882,241,261 15,725,596,864

    3,144,035,109 3,203,246,615 3,361,810,671 3,639,679,275

    1,134,044,791 756,029,860 378,014,930 0

    0 0 0 0

    508,052,852 578,036,884 663,377,693 767,445,059

    1,501,937,466 1,869,179,871 2,320,418,048 2,872,234,2166,388,708,406 8,507,053,943 11,101,231,599 14,269,691,805

    3228230059 3936608983 4800429337 5853800041

    378014930.2 378014930.2 378014930.2 378014930.2

    840971644.1 1025508241 1250538183 1524947031

    188080127.3 229351039.1 279678134.6 341048635.5

    703,818,489 1,182,821,295 1,771,381,739 2,491,128,396

    1,049,593,156 1,754,749,455 2,621,189,275 3,680,752,773

    9,532,743,514 11,710,300,558 14,463,042,270 17,909,371,080

    32,584,541,166 36,654,396,423 41,732,243,257 48,021,927,669

    388006816.8 481680352.9 597968778.7 742331835.1

    4.940874328 4.922976421 4.872604841 4.79987802

    0.737117951 0.874868307 0.828549271 0.791725494

  • 7/27/2019 Excel Bex Pharma

    15/44

    1. As other income shows abnormal growth rate so we assumed a smoother rate of 11%

    2. As the growth rate of intangible assets shows abnormal result so we have normalized it at 15

    3. Issued Share Capital is assumed to be constant over the next 5years

    4. Share Premium is assumed to be constant over the next 5years

    5. Excess of Issue Price over Face Value of GDRs are assumed to be constant over the next 5ye

    6. Capital Reserve on Merger is assumed to be constant over the next 5years

    7. Revaluation Surplus is assumed to be constant over the next 5years8. Tax-Holiday Reserve is assumed to be constant over the next 5years

    9. Long Term Borrowing-Current Maturity is one-fifth of the long term debt

    10. Fully Convertible, 5% Dividend, Preference Share is assumed to be constant over the next 5y

    11. Income Tax Payable is assumed to be 0 for the next 5 years

    12. Liability for Gratuity & WPPF accumulated to the previous year

    13.Deferred Tax Liability accumulated to the previous year

    14. Perpetual growth rate is 2%.

    15. Risk-free rate is 8%.

  • 7/27/2019 Excel Bex Pharma

    16/44

    .5%.

    ars

    ears

  • 7/27/2019 Excel Bex Pharma

    17/44

    Time Monthly closing - Bxpharma DGEN Bxpharma return

    30/12/2011 93.60 5,257.61 -0.058350101

    30/11/2011 99.40 5,268.55 0.143843498

    31/10/2011 86.90 5,036.50 -0.194624652

    30/09/2011 107.90 5,910.20 0.134595163

    31/08/2011 95.10 6,212.00 -0.122693727

    29/07/2011 108.40 6,459.62 0.348258706

    30/06/2011 80.40 6,117.23 0.019011407

    31/05/ 2011 78.90 5,758.26 -0.307287094

    29/04/ 2011 113.90 6,050.85 -0.055555556

    31/03/ 2011 120.60 6,352.10 0.172011662

    28/02/ 2011 102.90 5,203.08 -0.237777778

    30/01/ 2011 135.00 7,484.23 -0.000740192

    30/12/2010 135.10 8,290.41 -0.070199587

    30/11/2010 145.30 8,602.44 -0.033909574

    31/10/2010 150.40 7,957.12 0.006020067

    30/09/2010 149.50 7,097.38 -0.032988357

    31/08/2010 154.60 6,657.97 0.027242525

    29/07/2010 150.50 6,342.76 0.028708134

    30/06/2010 146.3 6,153.68 0

    31/05/ 2010 146.3 6,107.81 -0.212170167

    29/04/ 2010 185.70 5,654.88 0.018092105

    31/03/ 2010 182.40 5,582.33 0.095495495

    28/02/ 2010 166.50 5,560.56 -0.073971079

    30/01/ 2010 179.80 5,367.11 0.154043646

    30/12/ 2009 155.8 4,535.53 -0.025641026

    26/11/ 2009 159.9 4,380.95 -0.02559415

    29/10/ 2009 164.10 3,364.26 0.032075472

    30/09/ 2009 159.00 3,083.89 -0.004383219

    31/08/ 2009 159.70 2,941.28 -0.043139605

    30/07/ 2009 166.90 2,914.53 -0.151930894

    30/06/ 2009 196.80 3,010.26 0.344262295

    31/05/ 2009 146.4 2,572.18 -0.011478731

    30/04/ 2009 148.1 2,554.36 -0.037061118

    31/03/ 2009 153.8 2,446.92 0.003916449

    26/02/ 2009 153.2 2,570.96 -0.107746069

    29/01/ 2009 171.7 2,649.49 0.023852117

    30/12/2008 167.7 2,795.34 0.481448763

    30/11/2008 113.2 2,468.92 -0.336070381

    30/10/2008 170.50 2,748.60 0.249084249

    25/09/2008 136.50 2,966.82 0.248856359

    31/08/2008 109.3 2,791.20 0.066341463

    30/07/2008 102.5 2,761.05 0.03850050730/06/2008 98.70 3,000.49 0.238393977

    29/05/2008 79.70 3,167.99 0.027061856

    30/04/2008 77.60 3,072.85 0.018372703

    31/03/2008 76.20 3,016.49 0.2192

    28/02/2008 62.50 2,931.38 0.050420168

    31/01/2008 59.5 2,907.17 0.010186757

    30/12/2007 58.9 3,017.21 -0.122205663

    29/11/2007 67.1 2,971.11 -0.06022409

    31/10/2007 71.4 2,850.81 0.448275862

  • 7/27/2019 Excel Bex Pharma

    18/44

    30/09/2007 49.3 2,548.49 -0.015968064

    29/08/2007 50.1 2,455.08 -0.1005386

    31/07/2007 55.7 2,384.18 0.122983871

    28/06/2007 49.6 2,149.32 0.004048583

    31/05/2007 49.4 2,003.58 -0.048169557

    30/04/2007 51.9 1,743.33 -0.005747126

    29/03/2007 52.2 1,760.88 0.096638655

    28/02/2007 47.6 1,791.54 -0.136116152

    31/01/2007 55.1 1,805.12

    Covariance 0.006110757

    Variance of market return 0.008318305

    Beta 0.734615611

    Market return 0.022401635

    Market return -yearly 0.268819617

    9

  • 7/27/2019 Excel Bex Pharma

    19/44

    DGEN return

    -0.002078098 2007 2008 2009 2010 2011

    0.046074901 Mkt. P. 54.85833 104.4917 161.2833 157.70 101.92

    -0.147829845

    -0.048582557

    -0.038334444

    0.055971271

    0.062339919

    -0.0483538

    -0.047426214

    0.220833798

    -0.304793373

    -0.097243043

    -0.036272101

    0.081099725

    0.121134749

    0.065997038

    0.049697131

    0.03072646

    0.007508986

    0.080096639

    0.012995091

    0.003915655

    0.036044454

    0.183346715

    0.035285445

    0.302201843

    0.090916421

    0.048483075

    0.009178082

    -0.03180122

    0.170316003

    0.006978285

    0.04390538

    -0.048247208

    -0.029639679

    -0.052174601

    0.132212366

    -0.101753442

    -0.073553689

    0.062918512

    0.010919759

    -0.079800299-0.052872642

    0.030961485

    0.018684305

    0.029033766

    0.008329074

    -0.036472105

    0.015516087

    0.042198533

    0.118627109

  • 7/27/2019 Excel Bex Pharma

    20/44

    0.03804764

    0.029737688

    0.10927177

    0.072739796

    0.149283268

    -0.009966608

    -0.017113768

    -0.007523035

  • 7/27/2019 Excel Bex Pharma

    21/44

    Particulars 2011 2012 2013

    Inventory 2,291,844,631 3336959669 4069197414

    Accounts receivable 978,224,317 1265576866 1543285691

    Advance and prepayment 840,320,705 1340548247 1634708238

    Non-cash current asset 4,110,389,653 5,943,084,782 7,247,191,343

    Accounts payable 523798136 689641758.2 840971644.1

    Accrued expenses 101559917 154235770.7 188080127.3

    Other liabilities 1361452 394755425.5 868025326.4

    Non- STD Current liabilities 626719505 1238632954 1897077098

    Working capital 3,483,670,148 4,704,451,827 5,350,114,245

    Change in WC 1,220,781,679 645,662,418

    Particulars 2007 2008 2009

    Inventory 1,470,152,242 1,505,288,093 1,722,953,284

    Accounts receivable 499,680,792 503,916,401 694,111,730

    Advance and prepayment 685,915,465 544,509,106 699,204,450

    Non-cash current asset 2,655,748,499 2,553,713,600 3,116,269,464

    Accounts payable 271,814,118 263,176,822 409,898,122

    Accrued expenses 60,052,739 81,776,450 79,094,905

    Other liabilities 3,285,324 3,169,568 1,727,724

    Non- STD Current liabilities 335,152,181 348,122,840 490,720,751

    Working capital 2,320,596,318 2,205,590,760 2,625,548,713

  • 7/27/2019 Excel Bex Pharma

    22/44

    2014 2015 2016

    4962111993 6050961142 7378739294

    1881932887 2294890318 2798464074

    1993416521 2430837097 2964242008

    8,837,461,401 10,776,688,557 13,141,445,375

    1025508241 1250538183 1524947031

    229351039.1 279678134.6 341048635.5

    1437989308 2125077961 2954118416

    2692848588 3655294279 4820114082

    6,144,612,813 7,121,394,278 8,321,331,292

    794,498,568 976,781,465 1,199,937,014

    2010 2011

    1,983,809,444 2,291,844,631

    821,356,439 978,224,317

    779,129,620 840,320,705

    3,584,295,503 4,110,389,653

    432,315,660 523,798,136

    90,512,178 101,559,917

    1,507,899 1,361,452

    524,335,737 626,719,505

    3,059,959,766 3,483,670,148

  • 7/27/2019 Excel Bex Pharma

    23/44

    Risk-free rate 0.08

    Market return 0.268819617

    Beta 0.734615611

    Cost of equity 0.218709839

    Cost of debt 0.119093517

    After tax cost of debt 0.091796034

    Total market value of equity 23,565,467,016.00

    Book value of debt 3,896,034,840

    Weight of equity 0.86

    Weight of debt 0.14

    WACC 0.20

  • 7/27/2019 Excel Bex Pharma

    24/44

    Particulars 2012 2013 2014

    EBIT 2526623548 3039636997 3660667208

    EBIT (1-tax rate) 1947494918 2342920302 2821603872

    Depreciation 4004291313 4075748733 4158295916

    Capital expenditure -2,443,606,226 -2,822,839,289 -3,260,927,053

    Change in NWC 1,220,781,679 645,662,418 794,498,568

    Free cashflow 2,287,398,326 2,950,167,328 2,924,474,167

    Present value discount factor 0.83 0.69 0.58

    Present value of free cashflow 1,906,165,271.52 2,048,727,310.86 1,692,404,031.70

    Terminal value

    Enterprise value 14,839,006,606.13

    Cash 518,768,296

    Interest-bearing debt 3,896,034,840

    Equity value 11,461,740,062.13

    Value per share 45.53

    Depreciation 4004291313 531896689.8 614443872.9

  • 7/27/2019 Excel Bex Pharma

    25/44

    2015 2016 2017

    4412915517 5324619274

    3401428975 4104160665

    4253653928 4363810933

    -3,767,003,417 -4,351,619,804

    976,781,465 1,199,937,014

    2,911,298,021 2,916,414,779 2,974,743,075

    0.48 0.40

    1,403,982,456.10 1,172,041,690.49

    6615685845

    709801884.8 819958889.5

    M.R.K

  • 7/27/2019 Excel Bex Pharma

    26/44

    A.

    1 Dividend Per Share

    2 Revenue Per Share (Rs)

    3 Net Operating Profit Per Share (Rs)

    4 Free Reserves Per Share (Rs)

    5 Bonus in Equity Capital

    6 P/E ratio

    7 Dividend payout ratio

    8 Dividend yieldB.

    2 Gross Profit Margin(%)

    3 Cash Profit Margin(%)

    4 Adjusted Cash Margin(%)

    5 Net Profit Margin(%)

    6 Adjusted Net Profit Margin(%)

    7 Return On Capital Employed(%)

    8 Return On Net Worth(%)

    Ratio AnaInvestm

    Pr

    1 Operating Profit Margin(%)

  • 7/27/2019 Excel Bex Pharma

    27/44

    9 Adjusted Return on Net Worth(%)

    12 Return on Long Term Funds(%)

    13 Pretax Margin

    C.

    1 Current Ratio

    2 Quick Ratio

    3 Cash Ratio

    4 Defensive Interval

    5 Cash conversion cycle

    6 Debt Equity Ratio

    7 Long Term Debt Equity Ratio

    8 Debt Coverage Ratios

    10 Return on Assets

    11 Operating return on Assets

    Liquidit

  • 7/27/2019 Excel Bex Pharma

    28/44

    9 Debt to Asset ratio

    11 Financial Leverage ratio

    12 Financial Charges Coverage Ratio

    13 Fixerd charge coverage ratio

    D.

    1 Inventory Turnover Ratio

    2 Days of inventory on hand

    3 Debtors Turnover Ratio

    4 Investments Turnover Ratio

    5 Receivable turnover

    6 Days of sales Outstanding

    7 Fixed Assets Turnover Ratio

    8 Total Assets Turnover Ratio

    9 Payables turnover

    10 Number of days of payables

    11 Raw material turnover ratio

    12 Raw material holding periaod

    13 Working capital turnover

    14 Number of Days In Working Capital

    E.

    1 Material Cost Composition

    2

    Imported Composition of Raw Materials

    Consumed

    3 Selling Distribution Cost Composition

    4 Expenses as Composition of Total Sales

    F.

    1 Dividend payout Ratio

    2 Dividend Payout Ratio Net Profit

    3 Dividend Payout Ratio Cash Profit

    4 Dividend Yield

    5 Earning Retention Ratio

    6 Cash Earning Retention Ratio

    7 Adjusted Cash Flow Times

    8 Earnings Per Share9

    10 Book Value per share

    Profit &

    Cash Fl

    10 Interest Cover

    Manage

  • 7/27/2019 Excel Bex Pharma

    29/44

    (Sum of Dividend-Special one time dividend)/Number of

    outstanding Share

    Revenue/Weighted average number of share

    EBIT/Weighted average number of share

    Reserve/Weighted average number of share

    Market price per share/Earning per share

    Yearly Dividend per share/Earning per Share

    Dividend per share/Market price per share

    Operating income/revenue

    EBIT/Revenue

    gross profit/Revenue

    Cash flow from operating cash flows/Net sales

    Net income/ revenue

    EBIT/(Total Assets-Current liabilities)

    Net Income-Preferred dividend/Common Equity

    lysisent Valuation Ratios

    fitability Ratios

  • 7/27/2019 Excel Bex Pharma

    30/44

    Net Income/Average total Assets

    net income+ Interest expense (1 tax

    rate)/Average total Assets

    Operating income/Average total assets

    EBIT/ Average total Assets

    Net Income/Share Capital (Equity + Preference) +

    Reserves and Surplus + Long- term Loans Fictitious

    Assets

    EBT/Revenue

    Current Assets/Current Liabilitiescas + mar eta e securities + receiva es

    current liabilities

    cash + marketable securities/ Current Liabilitiescash + marketable securities + receivables/

    average daily expenditures

    Days of sales outstanding + Days of Inventory

    on hand - Number of days of payables

    Total Debt/ Total Share holders Equity

    Long term debt/Total shareholders equity

    CFO-cash dividend paid/Total debt

    And Solvency Ratios

  • 7/27/2019 Excel Bex Pharma

    31/44

    Total debt/Total Assets

    CFO + Cash payment for interest and income

    taxes/Cash payment for interestEarnings before interest and taxes/ Interest

    payments

    Average total assets/Average total liabilities

    Earnings before interest and taxes + lease

    payments/ Interest payments + lease payments

    Cost of goods sold/Average Inventory

    365/ Inventory turnover

    Net Credit Sales/Average Accounts Receivables

    Net earnings/Investment

    Annual Sales/Average receivables

    365/ Receivable turnover

    Revenue/Average net fixed assets

    Revenue/Average total assets

    Purchases or COGS/Average trade payables

    365/ Payables turnoverRaw materials consumed during the

    year/Average raw materials held

    365/Raw materials turnover

    Revenue/Average working capital

    Average Working Capital / (Revenue/365)

    Yearly Dividend per share/Earning per Share

    Total Dividend Payout / Net Profit

    Total Dividend Payout / CFO

    Dividend per share/Market price per share

    ((earnings per share - dividend per share) / earnings per

    share)* 100%

    (Net Income-Preferred dividend)/Weighted

    average number of common shares outstanding

    Total Shareholders equity-preferred stock/Total

    outstanding Share

    Loss Account Ratios

    ow Indicator Ratios

    ent Efficiency Ratios

  • 7/27/2019 Excel Bex Pharma

    32/44

    A.

    1 Dividend Per Share

    2 Dividend payout ratio

    3 Dividend yield

    B.

    1 Net Profit Margin(%)

    2 P/E ratio

    C.1 Current Ratio

    2 Debt Equity Ratio

    3 Financial Leverage ratio

    4 Debt to Asset ratio

    D.

    1 Inventory Turnover Ratio

    2 Receivable turnover

    3

    Total Assets Turnover

    Ratio

    4 Payables turnover

    5

    Working capital

    turnover

    3 Return on Assets

    Return on Equity

  • 7/27/2019 Excel Bex Pharma

    33/44

  • 7/27/2019 Excel Bex Pharma

    34/44

    2007

    (Sum of Dividend-Special one time dividend)/Number of outstanding Share 0.462505889

    Yearly Dividend per share/Earning per Share 0.15016425

    Dividend per share/Market price per share 0.008430914

    Net income/ revenue 0.09815553

    Market price per share/Earning per share 17.81114719

    Net Income/Average total Assets 0.029536978

    net income+ Interest expense (1 tax rate)/Average total Assets

    Net Income/Average total Equity 0.042791233

    Current Assets/Current Liabilities 1.795960727

    Total Debt/ Total Share holders Equity 0.44873426

    Average total assets/Average total liabilities 3.228490423Total debt/Total Assets 0.309742285

    Cost of goods sold/Average Inventory 1.338303557

    Annual Sales/Average receivables 7.198645354

    Revenue/Average total assets 0.300920166Purchases or COGS/Average trade payables 7.23843923

    Revenue/Average working capital 1.550043316

    Investment Valuation Ratios

    Profitability Ratios

    Liquidity And Solvency Ratios

    Management Efficiency Ratios

  • 7/27/2019 Excel Bex Pharma

    35/44

  • 7/27/2019 Excel Bex Pharma

    36/44

    2008 2009 2010 2011

    1.298867166 0.616020375 0.83541165 0.99969222

    0.299969322 0.149157476 0.199859246 0.21001937

    0.012430342 0.003819492 0.005297474 0.00980892

    0.135989665 0.127507766 0.162020265 0.1518997

    24.13202463 39.05165456 37.72727273 21.4110644

    0.036798487 0.03120563 0.049205931 0.05203437

    0.052184758 0.057023428 0.065834676 0.0699741

    1.099867857 2.979488251 2.463700938 2.69940539

    0.418122371 0.827344253 0.337941896 0.34476694

    3.391644336 2.208686706 3.959088567 3.90051012

    0.294842236 0.452757739 0.252583387 0.25637672

    1.330556716 1.489423219 1.672358333 1.79057034

    7.958000674 7.013647378 7.902595079 8.06588193

    0.270597678 0.24473513 0.303702322 0.34255743

    7.610363123 6.260596202 7.674115377 7.83452391

    1.818182743 1.854185714 2.121219836 2.2649222

  • 7/27/2019 Excel Bex Pharma

    37/44

    Year 2007 2008 2009 2010

    Current Ratio 1.795960727 1.099867857 2.979488251 2.463700938

    Dividend Per Share 0.462505889 1.298867166 0.616020375 0.83541165

    Net Profit Margin(%) 0.09815553 0.135989665 0.127507766 0.162020265

    0

    0.5

    1

    1.5

    2

    2.5

    3

    3.5

    2007 2008 2009 2010 201

    Current Ratio

    0

    0.2

    0.4

    0.6

    0.8

    1

    1.2

    1.4

    2007 2008 2009 2010 2011

    Dividend Per Share

  • 7/27/2019 Excel Bex Pharma

    38/44

    P/E ratio 17.81114719 24.13202463 39.05165456 37.72727273

    Return on Assets 0.029536978 0.036798487 0.03120563 0.049205931

    0

    0.02

    0.04

    0.06

    0.080.1

    0.12

    0.14

    0.16

    0.18

    2007 2008 2009 2010 201

    Net Profit Margin

    0

    5

    10

    15

    20

    25

    30

    35

    40

    45

    2007 2008 2009 2010 20

    P/E ratio

    0.02

    0.03

    0.04

    0.05

    0.06Return on Assets

  • 7/27/2019 Excel Bex Pharma

    39/44

    Year 2007 2008 2009 2010Return on Equity 0.042791233 0.052184758 0.057023428 0.065834676

    Inventory Turnover R 1.338303557 1.330556716 1.489423219 1.672358333

    Total Assets Turnove 0.300920166 0.270597678 0.24473513 0.303702322

    0

    0.01

    2007 2008 2009 2010 2011

    0

    0.01

    0.02

    0.03

    0.04

    0.05

    0.06

    0.07

    0.08

    2007 2008 2009 2010 2011

    Return on Equity

    0

    0.2

    0.4

    0.6

    0.8

    1

    1.2

    1.4

    1.6

    1.8

    2

    2007 2008 2009 2010 2011

    Inventory Turnover Ratio

    Invent

    Total Assets Turnover R

  • 7/27/2019 Excel Bex Pharma

    40/44

    Payables turnover 7.23843923 7.610363123 6.260596202 7.674115377

    Working capital turno 1.550043316 1.818182743 1.854185714 2.121219836

    0

    0.05

    0.1

    0.15

    0.2

    0.25

    0.3

    0.35

    .

    2007 2008 2009 2010 2011

    To

    0

    1

    2

    3

    4

    5

    6

    7

    8

    9

    2007 2008 2009 2010 2011

    Payables turnover

    0

    0.5

    1

    1.5

    2

    2.5

    2007 2008 2009 2010 2011

    Working capital turnov

  • 7/27/2019 Excel Bex Pharma

    41/44

    2011

    2.69940539

    0.99969222

    0.1518997

    1

    Current Ratio

    Dividend Per Share

  • 7/27/2019 Excel Bex Pharma

    42/44

    21.4110644

    0.05203437

    %)

    Net Profit Margin(%)

    11

    P/E ratio

    Return on Assets

  • 7/27/2019 Excel Bex Pharma

    43/44

    20110.0699741

    1.79057034

    0.34255743

    Return on Equity

    ory Turnover Ratio

    tio

  • 7/27/2019 Excel Bex Pharma

    44/44

    7.83452391

    2.2649222

    tal Assets Turnover Ratio

    Payables turnover

    er

    Working capital turnover